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ABSTRACT
Background High frequency chest wall oscillation
(HFCWO) is standard treatment for airway clearance in
the USA and has recently been introduced in the UK and
Europe. There is little published research comparing
HFCWO with airway clearance techniques (ACTs)
frequently used in the UK and Europe. The aim of this
study was to compare the short-term effects of HFCWO
with usual ACTs in patients with cystic ﬁbrosis
hospitalised with an infective pulmonary exacerbation.
Methods A 4-day randomised crossover design was
used. Patients received either HFCWO on days 1 and 3
and usual ACTs on days 2 and 4 or vice versa. Wet
weight of sputum, spirometry and oxygen saturation
were measured. Perceived efﬁcacy, comfort, incidence
of urinary leakage and preference were assessed. Data
were analysed by mixed model analysis.
Results 29 patients (72% male) of mean (SD) age 29.4
(8.4) years and mean (SD) forced expiratory volume in 1 s
(FEV1) percentage predicted (FEV1%) 38 (16.7)
completed the study. Signiﬁcantly more sputum was
expectorated during a single treatment session and over
a 24 h period (mean difference 4.4 g and 6.9 g,
respectively) with usual ACTs than with HFCWO
(p<0.001). No statistically signiﬁcant change in FEV1%o r
oxygen saturation was observed after either HFCWO or
usual ACTs compared with baseline. 17 patients (55%)
expressed a preference for their usual ACT.
Conclusions During both a ﬁnite treatment period and
over 24 h, less sputum was cleared using HFCWO than
usual ACT. HFCWO does not appear to cause any adverse
physiological effects and may inﬂuence adherence.
INTRODUCTION
The last four decades have seen improved survival
in patients with cystic ﬁbrosis (CF). The latest
ﬁgures estimate the median life expectancy of
individuals with CF born in 2000e3 to be approx-
imately 40 years.
1 Respiratory failure is the major
cause of morbidity and mortality in those with CF.
2
Accumulation of secretions in the CF airway
precipitates chronic infection, causing a progressive
deterioration in lung function and eventually
respiratory failure and death.
3 Airway clearance
techniques (ACTs) are an essential component of
the management of patients with CF and are
considered standard care.
4 There is a range of ACTs
which augment the normal mucus clearance
mechanisms of the lung to facilitate expectoration.
These techniques generally aim to promote secre-
tion clearance by altering airﬂow and mucus
viscosity.
Typically, high frequency chest wall oscillation
(HFCWO) produces compression of the chest wall
via an inﬂatable jacket linked to an air pulse
generator. The generator delivers an intermittent
ﬂow of air into the jacket which rapidly compresses
and releases the chest wall at a variety of frequen-
cies. Consequently, an oscillation in airﬂow within
the airways is achieved. HFCWO has been shown
to enhance central and peripheral mucus clearance.
5
A number of underlying mechanisms have been
hypothesised including increased airﬂow-mucus
interaction causing a reduction in viscolelasticity,
production of an expiratory airﬂow bias which
promotes a cephalad movement of mucus and the
enhancement and stimulation of ciliary activity.
67
Published short-term evidence has demonstrated
increased sputum clearance and improved pulmo-
nary function with HFCWO compared with no
treatment.
8 This and other studies have also
compared HFCWO with alternative ACTs. Some
have demonstrated increased sputum clearance
with HFCWO compared with postural drainage
and percussion (PD&P).
9e11 Others found no
signiﬁcant difference in sputum clearance between
HFCWO and PD&P,
81 21 3positive expiratory pres-
sure (PEP),
8 high frequency oral oscillation
13 or
intrapulmonary percussive ventilation.
14 Further-
more, some of these studies found no differences in
efﬁcacy related to pulmonary function between
HFCWO and PD&P,
81 21 3PEP,
81 5oscillating posi-
tive expiratory pressure (Flutter, manufactured by
Axcan Scandipharm Inc, Birmingham, AL, USA)
16
and high frequency oral oscillation.
13 One study
reported an improved outcome in forced expiratory
volume in 1 s (FEV1) in the longer term using
HFCWO compared with PD&P.
17
Few trials have compared HFCWO with alter-
native ACTs which are commonly used in the UK
and Europe by individuals with CF. Phillips et al
18
compared HFCWO (using the Hayek Cuirass) with
the active cycle of breathing techniques (ACBT) in
hospitalised paediatric patients. Signiﬁcantly more
sputum was cleared with the ACBT. The authors
concluded that HFCWO was not an effective
airway clearance treatment for children with CF. It
is difﬁcult to compare this study directly with those
above, as the Hayek Cuirass machine has a different
operating mode to the inﬂatable vest system.
A series of Cochrane systematic reviews have
found that no one ACT is superior in terms of
respiratory function and efﬁcacy.
19 Of a number of
published studies on HFCWO, only two were
deemed of sufﬁcient quality to be included in these
randomised control trial systematic reviews.
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Cystic ﬁbrosisHFCWO is widely used in the USA where it is considered
standard care in CF.
20 It has recently been introduced to the UK
and Europe, where the mainstay of care for airway clearance in
CF is the ACBT, autogenic drainage (AD) and other airway
clearance regimens using small devices.
4 In the USA these tech-
niques and devices tend to be considered adjuncts, with PD&P
and HFCWO remaining the most common ACTs.
20 While there
is a body of evidence which equates HFCWO and PD&P, there is
a need for further trials to compare HFCWO with alternative
ACTs to provide a more relevant evidence base for HFCWO in the
UK and Europe.
The aim of the present study was to compare the short-term
effects of HFCWO with patients’ usual ACTs in those with CF
admitted to hospital with an acute exacerbation of pulmonary
infection. The hypothesis was that HFCWO was superior to
patients’ usual ACTs.
METHODS
Study participants
All patients admitted to hospital who met the entry criteria
were invited to participate in the study. The inclusion criteria
were a diagnosis of CF (established by genotype or sweat
sodium>70 mmol/l orsweat chloride of >60 mmol/l), FEV1$20%
predicted, age $16 years and an infective pulmonary exacerba-
tion as deﬁned by Thornton et al.
21 Exclusion criteria were
current severe haemoptysis, rib fractures, pregnancy, inability to
give consent and those whose usual ACTwas HFCWO. Informed
written consent was obtained for all patients and the study was
approved by Brompton Hareﬁeld and National Heart and Lung
Institute research ethics committee.
Study design
A randomised crossover design was used to compare HFCWO
with patients’ usual ACTs, which allowed within-patient vari-
ability to be controlled. Over four consecutive days, patients
received either HFCWO therapy on days 1 and 3 and their
normal ACTon days 2 and 4 or vice versa. Allocation to HFCWO
or usual ACTon day 1 was determined using a computer-gener-
ated randomisation table.
Protocols
Patients performed their usual ACT or received HFCWO two
times daily at the same time. Before starting the study, each
patient’s usual ACT was reviewed by an experienced senior
respiratory physiotherapist. In addition, patients were fami-
liarised with HFCWO (The Vest). This involved the patients
using The Vest for a trial period the day before the start of the
study, during which time they were given the opportunity to
experience all three protocol frequencies at a variety of pressures.
Each airway clearance treatment session lasted 30 min and was
supervised by the same physiotherapist to ensure optimisation
and standardisation of usual ACTand HFCWO performance. All
nebulised and inhaled medications were taken before each
treatment session in accordance with the patients’ individual
regimens.
High frequency chest wall oscillation
The following regimen was identiﬁed as current best practice
following an in-depth review of the literature and discussion
with clinical experts in the USA. Using The Vest Airway
Clearance System Model 4 (Hill-Rom UK Ltd, Leicestershire,
UK), each patient was ﬁtted with an appropriately-sized, full
torso, inﬂatable, disposable vest connected to the air pulse
generator via two ﬂexible tubes. Patients remained in an upright
sitting position throughout the 30 min treatment session.
HFCWO was applied for 8 min at each of three frequencies in
sequence (10, 13 and 15 Hz) with each frequency followed by
a 2 min rest period. The pulse pressure was set according to
individual patient’s reported comfort at all three frequency
settings. During both the HFCWO and rest periods, patients
were instructed to huff or cough as they felt necessary in order to
expectorate loosened bronchial secretions.
Usual ACT
Usual ACTs were in accordance with the guidelines of the
International Physiotherapy Group for Cystic Fibrosis.
22 Patients
performedtheir usual ACT for30 min, and forpatients practising
an assisted ACT, the physiotherapist provided percussion.
Patients were allowed to perform combined ACTs where this was
their usual practice. This reﬂected current international practice
more accurately and recommendations that ACTs be adapted on
an individual basis.
23
Outcome measures
The primary outcome measure was wet weight of sputum
expectorated during a treatment session. Patients were
instructed to expectorate all sputum into a preweighed pot
during and for 30 min following each treatment session. They
were also instructed to collect sputum expectorated at all other
times during each 24 h period. All sputum collected was weighed
immediately following collection on weighing scales with an
accuracy of 0.01 g (BL310; Sartorious UK Ltd, Epsom, UK).
FEV1 was measured using a hand-held spirometer (2120;
Vitalograph Ltd, Buckingham, UK) in accordance with interna-
tionally agreed standards.
24 Measurements were taken immedi-
ately before and after a 30 min period following each treatment
session. Data were analysed using Spirotrac IV Version 4.30
software (Vitalograph Ltd).
Pulsed arterial oxygen saturation (SpO2) was measured
transcutaneously at rest, for 5 min immediately before, 30 min
during and 30 min immediately following each session. SpO2
was measured with a ﬁngertip pulse oximeter (Konica-Minolta
Pulsox-300i; Stowood Scientiﬁc Instruments, Oxford, UK). The
data were analysed using Download 2001 Version 2.8.0 software
(Stowood Scientiﬁc Instruments Ltd).
The perceived efﬁcacy and comfort of each ACT and the
incidence of urinary leakage during treatment were measured
using 10 cm visual analogue scales (VAS). Each day, after the last
treatment session, patients completed three 10 cm VAS with
reference to the ACT used that day. On the VAS used, 0 repre-
sented not at all effective/comfortable or no urinary leakage and
10 represented extremely effective/comfortable or a lot of urinary
leakage. On the fourth and ﬁnal day, participants were also asked
to indicate which ACT they would prefer.
An independent observer, blind to the daily method of airway
clearance used, performed the spirometry, weighed the sputum
samples and collected the 10 cm VAS throughout the study.
Statistical analysis
A sample size calculation determined the number of patients
required to test for superiority of HFCWO. This was based on
a difference of 4 g of sputum between the usual ACT and
HFCWO during a single treatment session. A square-root of
within SEM of 4 g at the 5% signiﬁcance level would require 24
patients to achieve 90% power. Data are presented as mean (SD),
median (IQR) or n (%) as appropriate. Continuous variables were
analysed using a mixed-effects linear regression model. This was
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are inherent to the design of a crossover trial. The order of
treatment randomisation and the day and time of treatment
were all entered into the model and their effect on the outcomes
was tested. For this trial, the results were also adjusted for the
method and position of treatment in the ACT session. In these
models, patients were entered as random effects since it was not
of interest to quantify the differences between individual
patients, but it was important to account for the repeated
measurements on each patient. The estimates of the ﬁxed effect
of ACT versus HFCWO are presented as mean (95% CI). A
p value of 0.05 was taken to be statistically signiﬁcant. All
analyses were conducted using Stata 9.2 (StataCorp).
RESULTS
Participants
Fifty patients were invited to participate in the study, 20
declined, 29 patients completed the study and 1 patient was
withdrawn due to a hypoglycaemic episode. Table 1 shows
demographic and baseline characteristics of the patients who
completed the study.
Twenty-nine patients were treated with intravenous antibi-
otics as part of their medical management. All participants
received two treatment sessions on each study day and all
treatment sessions were 30 min in duration. The mean (SD)
length of stay for patients was 14 (5) days and the mean day of
entry to the study was day 8 (3) days.
Usual ACT
Usual ACTs included the ACBT with modiﬁed PD&P (41%;
n¼12) and with modiﬁed PD alone (7%; n¼2), AD in sitting
(28%; n¼8) and with modiﬁed PD (7%; n¼2), PEP (7%; n¼2) and
Flutter (10%; n¼3).
Sputum weight
The wet weight of sputum expectorated with usual ACT
compared with HFCWO is shown in table 2. The mean weight
of sputum expectorated during a single treatment session and
over a 24 h period was signiﬁcantly greater with usual ACT than
with HFCWO. The mean difference in wet weight of sputum
expectorated during a treatment session was 4.4 g (p<0.001) and
the mean difference in wet weight of sputum expectorated over
a 24 h period was 6.9 g (p<0.001). These ﬁndings were not
affected by order, time, day or position of treatment.
No statistically signiﬁcant difference was observed in the
amount of sputum expectorated when using HFCWO or usual
ACT between treatments in a 24 h period.
Physiological measures
FEV1 and SpO2 measured before, during and after usual ACTand
HFCWO treatment sessions are shown in table 3.
Comfort, efﬁcacy and preference
The VAS scores for comfort, efﬁcacy and urinary leakage during
usual ACT compared with HFCWO are shown in table 4. No
signiﬁcant differences were observed in VAS scores for comfort or
urinary leakage between HFCWO and usual ACT. Patients scored
the efﬁcacy of their usual ACT signiﬁcantly higher than for
HFCWO (mean difference 14 mm; p¼0.002). This was not
affected by the order or day of treatment. Of those patients who
completed the study, 17 (55%) expressed a preference for their
usual ACT over HFCWO. Preference was not predicted by the
amount of sputum expectorated.
DISCUSSION
There have been few published comparisons between HFCWO
using a vest system with the ACTs of the ACBT and AD. This
short-term study, carried out in individuals with CF admitted to
hospital with an acute infective pulmonary exacerbation,
showed that signiﬁcantly more sputum was expectorated during
a single treatment session and over a 24 h period using the
patient’s usual ACT than with HFCWO. In addition, slightly less
sputum was expectorated at all other times (excluding treatment
sessions) on usual ACT days compared with HFCWO, but this
trend was not statistically signiﬁcant. These ﬁndings were
independent of order, time or day and position of treatment.
Neither HFCWO nor any of the usual ACTs were associated with
any adverse clinical events.
A possible factor contributing to the difference in sputum
clearance between HFCWO and usual ACT may have been the
number and frequency of forced expiratory manoeuvres (FEMs)
and the more gentle expiratory manoeuvres of the AD breath
that were performed with the usual ACTs. Some studies have
standardised the number of coughs and FEMs that patients
performed; however, at the time of designing the protocol, the
aim was to compare the regimens as currently practised inter-
nationally and the frequency of coughs and FEMs was neither
standardised nor counted. In retrospect, it would have been of
value to have counted the number of coughs and FEMs under-
taken during each regimen, but it had not been anticipated that
Table 2 Wet weight of sputum expectorated: HFCWO compared with usual ACT
Period of sputum
collection
Expectorated sputum wet weight (g)
Usual ACT HFCWO
Mean difference p Value Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Single treatment session 9.1 (7.9) 7.2 (3.0e14.2) 4.6 (4.1) 3.4 (1.5e6.7) 4.4 (3.5 to 5.4) <0.001
24 h (excluding treatment)* 22.4 (26.8) 12.9 (4.0e29.9) 24.9 (25.8) 15.3 (3.9e40.1)  1.5 ( 4.6 to 1.6) 0.352
24 h (including treatment) 39.8 (36.3) 25.5 (14.0e57.1) 34.3 (30.7) 26.3 (12.1e46.0) 6.9 (3.1 to 10.8) <0.001
Data are presented as mean (SD) or (95% CI) or median (IQR) as appropriate. Data are adjusted for randomisation, day, time and position of treatment using a mixed effects linear regression
model.
*Of 116 24-h sputum samples collected, two were discarded as they were incomplete.
ACT, airway clearance technique; HFCWO, high frequency chest wall oscillation.
Table 1 Patient demographics and baseline
characteristics (n¼29)
Age (years) 29.4 (8.4)
Male (%) 21 (72%)
Height (cm) 171 (9)
Weight (kg) 60 (11)
BMI (kg/m
2) 20.4 (2.6)
FEV1 (l) 1.46 (0.72)
FEV1% predicted 38 (16.7)
SpO2 (%) 94.3 (2.1)
Data are presented as mean (SD) or n (%) as appropriate.BMI, body mass
index; FEV1, forced expiratory volume in 1 s; SpO2, pulsed arterial oxygen
saturation.
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Cystic ﬁbrosisany differences between HFCWO and usual ACTs may be
aconsequenceofthenumberofFEMsorADbreaths. Theoretically,
during the three 8 min periods of HFCWO, fewer FEMs, coughs
or AD breaths would be undertaken than during an equivalent
period of the ACBT, AD, PEP or Flutter (all of which inherently
include FEMs or AD breaths at regular intervals). This difference
was supported by observations of the investigators. However,
manual cough counts are subject to observer error. Objective
cough monitoring using the Leicester Cough Monitor has only
recently been validated and should be considered for use in
further studies.
25
Components of patient satisfaction include efﬁcacy, comfort
and convenience. Some studies have formally evaluated patient
satisfaction and compliance. One study reported that 50% of
subjects chose HFCWO compared with the Flutter, and efﬁcacy
was the most frequently cited reason for this choice.
16 A later
study reported that HFCWO was not preferred over PD&P and
intrapulmonary percussive ventilation; furthermore, there was
no signiﬁcant correlation between treatment preference and
sputum weight.
14 The current study found that patients
perceived the efﬁcacy of HFCWO to be statistically signiﬁcantly
less than that of their usual ACT. However, nearly half (45%) of
patients expressed a preference for HFCWO. Preference may have
been affected by the novelty of a new treatment and it is
unknown whether this would continue in the long term.
There is no one recommended protocol for the application of
HFCWO in the literature. Published studies describe differing
numbers and duration of frequencies, length of treatment and
airway clearance. Frequencies of 10, 13 and 15 Hz were chosen as
it has been reported that maximum mucus transport occurs
between 11 and 15 Hz with a peak at 13 Hz.
5 6 In addition, the
highest oscillated tidal volume ﬂow (peak airﬂow) occurred
between 10 and15 Hz in patients with CF.
26 More recent research
recommends an individual “tuning” method to identify optimum
treatment frequencies. These have been shown to vary among
individuals and the oscillation waveform,
27 but it is unknown
whether “tuning” increases efﬁcacy.
It is possible that a practice effect could have occurred as all
patients were new to HFCWO. However, the protocol used in
this study did not require the patient to perform any newly
learnt physical technique. In addition, the statistical analysis
ensured data were adjusted for day of treatment and found no
effect. Alternatively, patients’ familiarity with their usual ACT
may also have had an effect on outcomes.
This study was powered to detect a difference of 4 g of
sputum expectorated during a single treatment session. Other
studies have been based on a difference of 3e3.5 g, which is
generally accepted as a clinically important difference.
28 29 Wet
weight sputum was felt to be an appropriate primary outcome
measure in this short-term study in an acute environment.
Previous work has found wet weight to be proportional to dry
weight sputum.
28 30 Emerging non-invasive means of measuring
airway clearance may be more sensitive indicators in the future
(eg, lung clearance index and electrical impedance tomography).
Considering the cost beneﬁt of HFCWO compared with other
ACTs and the differing healthcare systems in the USA and the
UK, it is unlikely that HFCWO will become the ﬁrst choice ACT
for most individuals in the UK. Further work needs to be
undertaken to identify the place of HFCWO in Europe. Patient
preference for a treatment regimen may positively inﬂuence
adherence to treatment in the short term, and nearly half the
patients who participated in this study preferred HFCWO to
their usual ACT. HFCWO is a safe treatment that facilitates
airway clearance in CF but, when compared with patients’ usual
ACTs, HFCWO led to the clearance of signiﬁcantly less sputum
during a single treatment session and over a 24 h period.
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Lung alert
Higher mortality from non-small cell lung cancer
reported in subjects treated with oestrogen and
progestin
The Women’s Heath Initiative (WHI) trial was a double-blind randomised placebo-controlled trial
that examined the health beneﬁts and risks of combined oestrogen and progestin in 16608
postmenopausal women in the USA. The study was stopped early as health risks were shown to
exceed beneﬁts. In this study, both the incidence and mortality from lung cancer during the
treatment and follow-up phases of the WHI (mean 7.9 years) were determined in a posthoc analysis.
No statistically signiﬁcant differences in the incidence of lung cancer were seen between
active (n¼109) and placebo (n¼85) groups (incidence 0.16% vs 0.13%; HR 1.23, 95% CI 0.92 to
1.63). More women died from lung cancer in the active (n¼73) compared with the placebo
(n¼40) groups, and more deaths were seen in non-small cell lung cancer in the active (n¼62;
0.09%) compared with the placebo (n¼31; 0.05%) groups. There were no statistically
signiﬁcant differences in deaths from small cell lung cancer in the active (n¼11; 0.02%)
compared with the placebo (n¼9; 0.01%) group.
Although there was no increase in the incidence of lung cancer in those on combined
treatment, there was an increase in deaths attributable to lung cancer, especially in non-small
cell disease. The authors speculate that combined hormone therapy stimulates growth of
existing non-small cell lung cancers. This should be discussed with women considering
combined hormone therapy, in particular those in a high-risk group.
< Chlebowski RT, Schwartz AG, Wakelee H, et al, for the Women’s Health Initiative Investigators. Oestrogen plus progestin and
lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomised controlled trial.
Lancet 2009;374:1243e51.
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